Stuart Peltz, Ph.D., founding CEO of PTC Therapeutics announced that he is stepping down after 25 years. Dr. Peltz has led PTC Therapeutics as its CEO since its founding in 1998 and pioneered the field of RNA-directed drug development. Matthew Klein, M.D., M.S., F.A.C.S., current COO, has been named the company’s CEO and will join the Board of Directors. The transition is effective immediately. Dr. Peltz will serve as a Senior Consultant to the company and join its Scientific Advisory Board following his retirement. Prior to joining PTC in 2019, Dr. Klein was CEO and Chief Medical Officer at BioElectron Technology, a biotechnology company focused on the development of redox-active small molecules for mitochondrial disease and related disorders of oxidative stress. PTC acquired BioElectron’s assets in 2019.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on PTCT:
- PTC Therapeutics initiated with a Market Perform at SVB Securities
- PTC Therapeutics management to meet with Cantor Fitzgerald
- PTC Therapeutics price target raised to $51 from $44 at RBC Capital
- PTC Therapeutics price target lowered to $66 from $68 at Cantor Fitzgerald
- PTC Therapeutics reports Q4 EPS ($2.35), consensus ($1.59)
